PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

Date: January 1, 2017
Pages: 407
Price:
US$ 10,995.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P1CC82CCFA3EN
Leaflet:

Download PDF Leaflet

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025

SUMMARY

Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. As a multisystem disorder, SLE is heterogeneous in nature-no two cases of lupus are alike-and can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The etiology of SLE and LN remains incompletely understood, but genetic and environmental factors have been shown to play pivotal roles in the development of the disease.

To date, the cornerstone of lupus therapy still relies on generic steroids and unspecific immunosuppressive agents; both of which are associated with severe adverse events (SAEs) and contribute significantly to the morbidity and mortality in lupus. The much anticipated approval of Benlysta (belimumab) in 2011 had only a small impact on the treatment paradigm, and off-label Rituxan/MabThera (rituximab) remains the market leader in terms of sales. R&D efforts in lupus are high, however late-stage clinical failure remains a major barrier to market entry. The anticipated release of six new pipeline agents for SLE and LN will have the potential to revolutionize the lupus treatment. GlobalData expects the global SLE and LN market-which, for the purposes of this report, comprises the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan)-to expand during the next decade at an astonishing CAGR of 10.6%, reaching total sales of $3.2 billion by 2025.

HIGHLIGHTS

KEY QUESTIONS ANSWERED
  • Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the SLE and LN marketplace.
  • What will be the effect of recent and upcoming biologics on the SLE and LN treatment landscape?
  • How will the upcoming first-in-class and me-too pipeline agents be received in the different markets?
  • What research and development (R&D) strategies will companies leverage to compete in the future SLE and LN marketplace?
  • Which patient population(s) are most likely to be targeted by newly introduced pipeline agents?
Key Findings
  • GlobalData has calculated that the global SLE and LN market generated about $1.2 billion in sales in 2015. This global market is expected to grow by an astonishingly strong compound annual growth rate (CAGR) of 10.6% from 2015-2025, reaching annual sales of $3.2 billion by the end of the forecast period. The majority of this growth will occur in the US, driven by an increased diagnosed disease prevalence of SLE and LN and the launch of three new first-in-class pipeline drugs (anifrolumab, Orencia [abatacept], and Lupuzor) and three improved therapeutic options (atacicept, blisibimod, and voclosporin). The SLE and LN market in the US is expected to grow at a CAGR of 10.4%, reaching sales of $2.8 billion by 2025. GlobalData estimates that sales in the 5EU to grow at a CAGR of 14.1% during the next 10 years, reaching $312.4m by 2025, while Japan will experience the lowest growth with a CAGR of 9.8%.
  • KOLs interviewed by GlobalData repeatedly identified the need for efficacious drugs as the most important clinical unmet need, with reducing lupus morbidity and mortality and the development of sensitive and reliable biomarkers for diagnosis and disease management as key areas of need as well.
  • GlobalData anticipates that opportunities will center on the development of safer and more efficacious drugs to treat the various disease manifestations in lupus.
SCOPE
  • Overview of SLE and LN, including epidemiology, etiology, pathophysiology, as well current routine SLE and LN recommendations of all 7MM covered.
  • Top-line SLE and LN market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the SLE and LN market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the global SLE and LN marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
REASONS TO BUY

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global SLE and LN market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the SLE and LN market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
1 TABLE OF CONTENTS

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 DISEASE OVERVIEW

3.1 Etiology and Pathophysiology
  3.1.1 Etiology
  3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
3.4 Quality of Life

4 EPIDEMIOLOGY

4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
  4.3.1 SLE and LN Prevalence
  4.3.2 LN Classification
4.4 Forecast Methodology
  4.4.1 Sources Used
  4.4.2 Forecast Assumptions and Methods
  4.4.3 Sources Not Used
4.5 Epidemiological Forecast for SLE and LN (2015-2025)
  4.5.1 Diagnosed Prevalent Cases of SLE
  4.5.2 Age-Specific Diagnosed Prevalent Cases of SLE
  4.5.3 Sex-Specific Diagnosed Prevalent Cases of SLE
  4.5.4 Age-Standardized Diagnosed Prevalence of SLE
  4.5.5 Diagnosed Prevalent Cases of SLE Segmented by Severity
  4.5.6 Diagnosed Prevalent Cases of LN
  4.5.7 Diagnosed Prevalent Cases of LN Segmented by Class
4.6 Discussion
  4.6.1 Epidemiological Forecast Insight
  4.6.2 Limitations of the Analysis
  4.6.3 Strengths of the Analysis

5 DISEASE MANAGEMENT

5.1 Diagnosis Overview
  5.1.1 SLE Diagnosis
  5.1.2 LN Diagnosis
5.2 Treatment Overview
  5.2.1 Treatment Guidelines and Leading Prescribed Drugs
5.3 US
  5.3.1 Diagnosis
  5.3.2 Clinical Practice
5.4 France
  5.4.1 Diagnosis
  5.4.2 Clinical Practice
5.5 Germany
  5.5.1 Diagnosis
  5.5.2 Clinical Practice
5.6 Italy
  5.6.1 Diagnosis
  5.6.2 Clinical Practice
5.7 Spain
  5.7.1 Diagnosis
  5.7.2 Clinical Practice
5.8 UK
  5.8.1 Diagnosis
  5.8.2 Clinical Practice
5.9 Japan
  5.9.1 Diagnosis
  5.9.2 Clinical Practice

6 COMPETITIVE ASSESSMENT

6.1 Overview
6.2 Strategic Competitor Assessment
6.3 Product Profiles - Major Brands, Small Molecules
  6.3.1 Antimalarials (numerous brand names)
  6.3.2 Steroids (numerous brand names)
  6.3.3 Methotrexate (numerous brand names)
  6.3.4 Mycophenolate Mofetil (numerous brand names)
  6.3.5 Cyclophosphamide (numerous brand names)
  6.3.6 Azathioprine (numerous brand names)
  6.3.7 Calcineurin Inhibitors (numerous brand names)
6.4 Product Profiles - Major Brands, Biologics
  6.4.1 Benlysta (belimumab)
  6.4.2 Rituxan (rituximab)
6.5 Minor Therapeutic Classes

7 UNMET NEEDS ASSESSMENT AND OPPORTUNITY ANALYSIS

7.1 Overview
7.2 Drugs with Superior Efficacy and Safety Profiles, Particularly for LN
  7.2.1 Unmet Need
  7.2.2 Gap Analysis
  7.2.3 Opportunity
7.3 Refined Clinical Trial Design Tailored to Heterogeneous Lupus Patient Populations
  7.3.1 Unmet Need
  7.3.2 Gap Analysis
  7.3.3 Opportunity
7.4 Reduced Morbidity and Mortality in Lupus Patients
  7.4.1 Unmet Need
  7.4.2 Gap Analysis
  7.4.3 Opportunity
7.5 Improved Physician Education
  7.5.1 Unmet Need
  7.5.2 Gap Analysis
  7.5.3 Opportunity
7.6 Sensitive and Reliable Biomarkers for Diagnosis and Disease Management
  7.6.1 Unmet Need
  7.6.2 Gap Analysis
  7.6.3 Opportunity
7.7 Increased Compliance Rates for SOC SLE and LN Therapies
  7.7.1 Unmet Need
  7.7.2 Gap Analysis
  7.7.3 Opportunity

8 PIPELINE ASSESSMENT

8.1 Overview
8.2 Clinical Trial Mapping
  8.2.1 Clinical Trials by Therapy Type
8.3 Promising Drugs in Late-Stage Clinical Development
  8.3.1 Blisibimod
  8.3.2 Atacicept
  8.3.3 Orencia (abatacept)
  8.3.4 Anifrolumab
  8.3.5 Lupuzor (IPP-201101, P-140)
  8.3.6 Voclosporin
8.4 Promising Drugs in Early-Stage Clinical Development
  8.4.1 Overview
8.5 Other Drugs in Clinical Development
8.6 Biosimilars
  8.6.1 Overview
  8.6.2 Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases
  8.6.3 Biosimilars in the Immunology Community
  8.6.4 By the Numbers: Biosimilars in Development for Potential Off-Label Use in SLE and LN
  8.6.5 The Impact of Biosimilars Will Be Felt Throughout the Pharmaceutical Industry
  8.6.6 Uptake of Biosimilars for SLE and LN Is Expected to Vary by Country/Region
  8.6.7 Biosimilars Forecast for SLE and LN

9 CURRENT AND FUTURE PLAYERS

9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
  9.3.1 GlaxoSmithKline
  9.3.2 Roche
  9.3.3 Bristol-Myers Squibb
  9.3.4 AstraZeneca
  9.3.5 Merck KGaA
  9.3.6 Anthera Pharmaceuticals
  9.3.7 Aurinia Pharmaceuticals
  9.3.8 ImmuPharma
  9.3.9 Pfizer

10 MARKET OUTLOOK

10.1 Global Markets
  10.1.1 Forecast
  10.1.2 Drivers and Barriers - Global Issues
10.2 US
  10.2.1 Forecast
  10.2.2 Key Events
  10.2.3 Drivers and Barriers
10.3 5EU
  10.3.1 Forecast
  10.3.2 Key Events
  10.3.3 Drivers and Barriers
10.4 Japan
  10.4.1 Forecast
  10.4.2 Key Events
  10.4.3 Drivers and Barriers

11 APPENDIX

11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
  11.4.1 Diagnosed SLE and LN Patients
  11.4.2 Drugs Included in Each Therapeutic Class
  11.4.3 Percent Drug-Treated Patients
  11.4.4 Launch and Patent Expiry Dates
  11.4.5 General Pricing Assumptions
  11.4.6 Individual Drug Assumptions
  11.4.7 Generic Erosion
  11.4.8 Pricing of Pipeline Agents
11.5 Primary Research - KOLs Interviewed for this Report
11.6 Primary Research - Prescriber Survey
11.7 About the Authors
  11.7.1 Analyst
  11.7.2 Therapy Area Directors
  11.7.3 Epidemiologists
  11.7.4 Global Director of Therapy Analysis and Epidemiology
11.8 About GlobalData
11.9 Disclaimer

LIST OF FIGURES

Figure 1: Overview of the Etiology and Pathogenesis of SLE
Figure 2: Integrated Hypothesis for the Pathogenesis of SLE
Figure 3: SLE Forecast Case Flow Map
Figure 4: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Both Sexes, N, 2015-2025
Figure 5: 7MM, Diagnosed Prevalent Cases of SLE, by Age, Both Sexes, N, 2015
Figure 6: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, By Sex, N, 2015
Figure 7: 7MM, Age-Standardized Diagnosed Prevalence (Cases per 100,000 Population) of SLE, All Ages, by Sex, 2015
Figure 8: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Men and Women, By Severity, N, 2015
Figure 9: 7MM, Diagnosed Prevalent Cases of LN, All Ages, Both Sexes, N, 2015‒2025
Figure 10: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by WHO Classification, 2015
Figure 11: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by ISN/RPS Classification, 2015
Figure 12: Overview of the Treatment Management of SLE and LN
Figure 13: SLE and LN Therapeutics - Clinical Trials by Type of Therapy and Development Stage, December 2016
Figure 14: SLE and LN - Key Phase II‒III Clinical Trials, 2016
Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in SLE and LN, 2015-2025
Figure 16: Company Portfolio Gap Analysis in SLE and LN, 2015-2025
Figure 17: Average Annual Cost of Therapy (ACOT) for SLE and LN, 2016
Figure 18: Global (7MM) Sales for SLE and LN by Country/Region, 2015 and 2025
Figure 19: Global (7MM) Sales for SLE and LN by Region, 2015‒2025
Figure 20: Global (7MM) Sales for SLE and LN by Drug, 2015 and 2025
Figure 21: Sales for SLE and LN by Drug Class in the US, 2015
Figure 22: Sales for SLE and LN by Drug Class in the 5EU, 2015 and 2025
Figure 23: Global Sales for SLE and LN by Country in the 5EU, 2015 and 2025
Figure 24: Global Sales for SLE and LN by Country in the 5EU, 2015‒2025
Figure 25: Sales for SLE and LN by Drug Class in Japan, 2015 and 2025

COMPANIES MENTIONED

GlaxoSmithKline
Roche
Bristol-Myers Squibb
AstraZeneca
Merck KGaA
Anthera Pharmaceuticals
Aurinia Pharmaceuticals
ImmuPharma
Pfizer

GlobalData foresees that seven products could potentially enter the lupus market during the 2012-2022 forecast period. The launch of new biologic drugs will increase treatment options, improve treatment management, and drive growth in the SLE and LN markets. Although the need for safe and effective new treatments is paramount for patients with lupus, products in the pipeline are expected to face many challenges in gaining patient share following their entry into the lupus market.

New entrants will be required to demonstrate their clinical benefits to gain physicians' and patients' confidence for their use, overcome reimbursement challenges, and will face increasing competition from competing biologic products and inexpensive, potent immunosuppressive and steroid therapies.

The development of new drugs that are more efficacious and safer than currently available treatments remains the most pressing unmet need for the management of patients with SLE and LN.

With the purchase of a site or global license of GlobalData's report "PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event Driven Update", you will receive an interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy, and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.

The material was prepared in May, 2015.

LIST OF TABLES

Table 1: Symptoms of SLE
Table 2: The 1982 Revised ACR Criteria For Classification of Systemic Lupus Erythematosus
Table 3: WHO and ISN/RPS Classification Systems for LN
Table 4: Risk Factors for SLE
Table 5: 7MM, Sources Used for Diagnosed Prevalence of SLE
Table 6: 7MM, Sources Used for Diagnosed Prevalence of Mild and Moderate/Severe SLE
Table 7: 7MM, Sources Used for Diagnosed Prevalence of LN
Table 8: 7MM, Sources Used for Diagnosed Prevalent Cases of LN Classified by the WHO Classification
Table 9: 7MM, Sources Used for Classifying LN by the ISN/RPS Classification
Table 10: 7MM, Sources Not Used in Epidemiological Analysis of SLE
Table 11: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Both Sexes, N, Select Years 2015-2025
Table 12: 7MM, Age-Specific Diagnosed Prevalent Cases of SLE, Both Sexes, N, Row (%), 2015
Table 13: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, By Sex, N, Row (%), 2015
Table 14: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Men and Women, By Severity, N, Row (%), 2015
Table 15: 7MM, Diagnosed Prevalent Cases of LN, All Ages, Both Sexes, N, Select Years 2015-2025
Table 16: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by WHO Classification, Row (%), 2015
Table 17: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by ISN/RPS Classification, Row (%), 2015
Table 18: Updated (1997) ACR Criteria for Classification of SLE
Table 19: The SLICC Clinical and Immunologic Criteria for Classification of SLE
Table 20: WHO and ISN/RPS Classifications of LN
Table 21: Treatment Guidelines for SLE and LN
Table 22: Most Prescribed Drugs for SLE and LN by Class in the Global Markets, 2015
Table 23: Country Profile - US
Table 24: Country Profile - France
Table 25: Country Profile - Germany
Table 26: Country Profile - Italy
Table 27: Country Profile - Spain
Table 28: Country Profile - UK
Table 29: Country Profile - Japan
Table 30: Leading Treatments for SLE and LN, 2016
Table 31: Product Profile - Hydroxychloroquine
Table 32: Efficacy of Antimalarial Therapy in Lupus
Table 33: Safety of Antimalarial Therapy in Lupus
Table 34: Antimalarial Therapy SWOT Analysis, 2016
Table 35: Global Sales Forecasts ($m) of Antimalarials for SLE and LN Therapy, 2015-2025
Table 36: Product Profile - Steroids
Table 37: Efficacy of Steroids in SLE Patients
Table 38: Safety of Long-Term Prednisone Use
Table 39: Steroids SWOT Analysis, 2016
Table 40: Global Sales Forecasts ($m) of Steroids for SLE and LN Therapy, 2015-2025
Table 41: Product Profile - Methotrexate
Table 42: Steroid-Sparing Effect of Methotrexate
Table 43: Safety of Methotrexate
Table 44: Methotrexate SWOT Analysis, 2016
Table 45: Global Sales Forecasts ($m) of Methotrexate for SLE and LN Therapy, 2015-2025
Table 46: Product Profile - Mycophenolate Mofetil
Table 47: Efficacy of Mycophenolate Mofetil
Table 48: Safety of Mycophenolate Mofetil
Table 49: Mycophenolate Mofetil SWOT Analysis, 2016
Table 50: Global Sales Forecasts ($m) of Mycophenolate Mofetil for SLE and LN Therapy, 2015-2025
Table 51: Product Profile - Cyclophosphamide
Table 52: Efficacy of Cyclophosphamide
Table 53: Safety of Cyclophosphamide
Table 54: Cyclophosphamide SWOT Analysis, 2016
Table 55: Global Sales Forecasts ($m) of Cyclophosphamide for SLE and LN Therapy, 2015-2025
Table 56: Product Profile - Azathioprine
Table 57: Efficacy of Azathioprine
Table 58: Safety of Azathioprine
Table 59: Azathioprine SWOT Analysis, 2016
Table 60: Global Sales Forecasts ($m) of Azathioprine for SLE and LN Therapy, 2015-2025
Table 61: Product Profile - Calcineurin Inhibitors
Table 62: Efficacy of Calcineurin Inhibitors
Table 63: Safety of Calcineurin Inhibitors
Table 64: Calcineurin Inhibitors SWOT Analysis, 2016
Table 65: Global Sales Forecasts ($m) of Calcineurin Inhibitors for SLE and LN Therapy, 2015-2025
Table 66: Product Profile - Benlysta
Table 67: Efficacy of Benlysta
Table 68: Safety of Benlysta
Table 69: Benlysta SWOT Analysis, 2016
Table 70: Global Sales Forecasts ($m) of Benlysta for SLE and LN Therapy, 2015-2025
Table 71: Product Profile - Rituxan
Table 72: Efficacy of Rituxan
Table 73: Safety of Rituxan
Table 74: Rituxan SWOT Analysis, 2016
Table 75: Global Sales Forecasts ($m) of Rituxan for SLE and LN Therapy, 2015-2025
Table 76: Summary of Minor Therapeutic Classes for the Treatment of SLE and LN, 2016
Table 77: Unmet Need and Opportunity in SLE and LN, 2016
Table 78: Key Late-Stage Pipeline Agents for SLE and LN, 2016
Table 79: Product Profile - Blisibimod
Table 80: Blisibimod SWOT Analysis, 2016
Table 81: Global Sales Forecasts (7MM) for Blisibimod in SLE and LN, 2015-2025
Table 82: Product Profile - Atacicept
Table 83: Atacicept SWOT Analysis, 2016
Table 84: Global Sales Forecasts ($m) for Atacicept in SLE and LN, 2015-2025
Table 85: Product Profile - Orencia
Table 86: Orencia SWOT Analysis, 2016
Table 87: Global Sales Forecasts ($m) for Orencia in SLE and LN, 2015-2025
Table 88: AstraZeneca’s Anifrolumab - Key Phase II and Phase III Clinical Trials
Table 89: Product Profile - Anifrolumab
Table 90: Anifrolumab SWOT Analysis, 2016
Table 91: Global Sales Forecasts ($m) for Anifrolumab in SLE and LN, 2015-2025
Table 92: Product Profile - Lupuzor
Table 93: Lupuzor SWOT Analysis, 2016
Table 94: Global Sales Forecasts ($m) for Lupuzor in SLE and LN, 2015-2025
Table 95: Product Profile - Voclosporin
Table 96: Voclosporin SWOT Analysis, 2016
Table 97: Global Sales Forecasts ($m) for Voclosporin in SLE and LN, 2015-2025
Table 98: Other Promising Clinical-Stage Drugs in Development for SLE/LN, 2016
Table 99: Drugs in Development for SLE and LN, 2016
Table 100: Biosimilars Pipeline for RA, 2016
Table 101: Global Sales Forecasts ($m) for Biosimilars (Rituximab and Abatacept) in SLE and LN, 2015-2025
Table 102: Key Companies in the SLE and LN Market in the 7MM, 2016
Table 103: GSK’s SLE and LN Portfolio Assessment, 2016
Table 104: Roche’s SLE and LN Portfolio Assessment, 2016
Table 105: BMS’ SLE and LN Portfolio Assessment, 2016
Table 106: AstraZeneca’s SLE and LN Portfolio Assessment, 2016
Table 107: Merck KGaA’s SLE and LN Portfolio Assessment, 2016
Table 108: Anthera’s SLE and LN Portfolio Assessment, 2016
Table 109: Aurinia’s SLE and LN Portfolio Assessment, 2016
Table 110: ImmuPharma’s SLE and LN Portfolio Assessment, 2016
Table 111: Pfizer’s SLE and LN Portfolio Assessment, 2016
Table 112: Global (7MM) Sales Forecasts ($m) for SLE and LN, 2015-2025
Table 113: SLE and LN Market - Global Drivers and Barriers, 2015‒2025
Table 114: Sales Forecasts ($m) for SLE and LN in the US, 2015-2025
Table 115: Key Events Impacting Sales for SLE and LN in the US, 2015-2025
Table 116: SLE and LN Market - Drivers and Barriers in the US, 2015‒2025
Table 117: Sales Forecasts ($m) for SLE and LN in the 5EU, 2015-2025
Table 118: Key Events Impacting Sales for SLE and LN in the 5EU, 2015-2025
Table 119: SLE and LN Market - Drivers and Barriers in the 5EU, 2015‒2025
Table 120: Sales Forecasts ($m) for SLE and LN in Japan, 2015-2025
Table 121: Key Events Impacting Sales for SLE and LN in Japan, 2015-2025
Table 122: SLE and LN Market - Drivers and Barriers in Japan, 2015‒2025
Table 123: Key Historical and Projected Launch Dates for SLE and LN
Table 124: Key Historical and Projected Patent Expiry Dates for SLE and LN
Table 125: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Skip to top


Ask Your Question

PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: